Physician profile
Gary J Barsky
NPI 1881756633
$6,410.92
in general payments reported to CMS, 2019-2025
24 companies · $774 in 2025
The $774 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $865 · 2020: $843 · 2021: $1,078 · 2022: $888 · 2023: $1,096 · 2024: $867 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,574 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,573.63 |
| Education | $163.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,694.52 | 2019-2025 | Skyrizi, Rinvoq |
| Amgen INC. | $1,154.44 | 2020-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $732.98 | 2020-2025 | Dupixent |
| Janssen Biotech, INC. | $498.21 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharmaceuticals Corporation | $448.50 | 2019-2025 | |
| Lilly USA, LLC | $433.00 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $369.92 | 2019-2025 | |
| Genzyme Corporation | $244.40 | 2020-2025 | |
| Vyne Pharmaceuticals INC. | $149.15 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $134.71 | 2019-2025 | |
| Celgene Corporation | $108.41 | 2019 | |
| Ucb, INC. | $77.87 | 2019-2023 | Cimzia |
| Galderma Laboratories, L.P. | $65.56 | 2024 | |
| Allergan, INC. | $42.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $41.90 | 2023 | Sotyktu |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $41.76 | 2021-2023 | Adbry |
| Mayne Pharma Commercial LLC | $33.33 | 2020 | |
| Dermira, INC. | $24.29 | 2020 | |
| Sandoz INC. | $23.78 | 2023 | Hyrimoz |
| Helsinn Therapeutics (U.S.), INC. | $23.55 | 2019 | |
| Verrica Pharmaceuticals INC. | $22.54 | 2024 | Ycanth |
| Sanofi-Aventis U.S. LLC | $20.00 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.07 | 2019 | |
| Arcutis Biotherapeutics, INC. | $13.03 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Barsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.